Pseudo addiction

Pseudo addiction was a term used in Purdue Pharma’s OxyContin promotion to recast behavior that could look like drug seeking as a response to inadequately relieved pain. In the book, the term matters not as a neutral clinical label but as a persuasive distinction: it offered doctors and patients a way to interpret opioid-seeking behavior as evidence of pain rather than addiction, while the video presenting the idea also minimized the medication’s risks. Its force depended in part on a claim about addiction rates whose source, the book explains, did not support the weight placed upon it.

A distinction framed as an explanation

The phrase appeared in Purdue Pharma’s video I Got My Life Back: Patients in Pain Tell Their Story, narrated by South Carolina pain specialist Dr. Alan Spanos. The narrator described patients who appeared to be seeking opioids as people pursuing pain relief, and presented that conduct as something that could be mistaken for drug addiction. The label therefore supplied an interpretive answer to a difficult clinical distinction: behavior associated with seeking medication did not necessarily mean addiction, the video argued, because it could instead reflect a continuing need for pain relief.

That distinction was presented within a video that praised OxyContin’s effects on patients’ quality of life while minimizing its risks. The book’s account places the term in this context, rather than treating it as an isolated definition. It helped make a favorable interpretation of opioid-seeking available at the same time that the video promoted the drug. A reader could encounter a patient’s pursuit of medication not as a warning sign in itself, but as a possible consequence of pain that remained untreated.

The statistic behind the reassurance

The video’s discussion of pseudo addiction was paired with a repeated claim that opioid analgesics caused addiction in less than 1 percent of patients. The book traces that figure to a one-paragraph letter to the editor published in the New England Journal of Medicine in 1980. Much later, one of the letter’s authors explained that it had never been intended as a conclusion about the risks of long-term opiate use. The narrow source and the broad claim were not equivalent: a brief letter about a different matter could not, as presented in the video, establish a general rate of addiction from long-term opioid treatment.

The book describes the statistic’s circulation as a kind of telephone game. At Purdue’s Dine ’n’ Dash gatherings and in doctors’ offices, from the coalfields to the California coast, the letter was repeated and altered until what people were hearing no longer resembled the authors’ original intention. The pseudo-addiction explanation and the under-1-percent figure worked in tandem rhetorically: one offered a way to reinterpret behavior that might raise concern, while the other supplied an apparently reassuring estimate of risk. The evidence in the book establishes their combined presence in promotion; it does not make the estimate a valid measure of long-term risk.

Promotion and distribution

The video was part of a substantial promotional effort. By the end of 2000, Purdue Pharma had distributed 15,000 copies. Doctors’ offices made the video available for checkout, placing its account of pain, medication-seeking, and addiction within settings where patients and prescribers could encounter it. Purdue Pharma had not submitted it to the U.S. Food and Drug Administration for review, although agency review was required.

The surrounding marketing environment had few industry or federal guidelines, according to the cited Government Accountability Office report. Voluntary industry guidelines were issued in July 2002 by the Pharmaceutical Research and Manufacturers of America; the Office of Inspector General at the U.S. Department of Health and Human Services issued its own voluntary guidelines in April 2003. These later dates help situate the video’s distribution: its broad circulation preceded those guidelines. The book also notes that Purdue Pharma handpicked physicians, connecting the video to a wider promotional practice of selecting medical voices rather than presenting the term as a concept developed independently of marketing.

Medical judgment and the book’s larger question

A year after appearing in the video, Dr. Spanos lectured that patients with chronic noncancer pain should be trusted to decide how many painkillers they could take without overdosing. He reasoned that they would simply “go to sleep” before they stopped breathing. The lecture extended the same confidence in patients’ self-regulation that made the video’s distinction consequential: it treated a person seeking pain medication as a case in which the danger of addiction or overdose could be discounted. The book places this confidence alongside an earlier belief, expressed by doctors treating wounded Civil War veterans, that patients could be trusted with morphine. The echo makes the argument appear less like a new discovery than a recurring assurance about opioid use.

Pseudo addiction thus sits at a boundary the book repeatedly examines: the boundary between pain treatment and addiction, and between a medical interpretation of drug-seeking and a warning that opioid use may be becoming dangerous. The term could direct attention toward pain that needed relief, but in the promotional setting described here it also supported an account that minimized risk. Its significance lies in that double function. It named a possible misreading of patients’ behavior while being circulated alongside a statistic that itself had been detached from the limited source that produced it.